^
Association details:
Biomarker:No biomarker
Cancer:Fallopian Tube Cancer
Drug:Avastin (bevacizumab) (VEGF-A inhibitor) +
Lynparza (olaparib) (PARP inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Title:

Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer

Published date:
04/28/2021
Excerpt:
Olaparib plus bevacizumab is recommended for use within the Cancer Drugs Fund as an option for maintenance treatment of advanced (International Federation of Gynecology and Obstetrics [FIGO] stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults when...there has been a complete or partial response after first-line platinum-based chemotherapy plus bevacizumab